These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7945739)

  • 21. Depressive symptoms and schizophrenia a psychopharmacological approach.
    Mauri MC; Bravin S; Fabiano L; Vanni S; Boscati L; Invernizzi G
    Encephale; 1995; 21(5):555-8. PubMed ID: 8529564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depression in patients with schizophrenia during an acute psychotic episode.
    Tapp A; Kilzieh N; Wood AE; Raskind M; Tandon R
    Compr Psychiatry; 2001; 42(4):314-8. PubMed ID: 11458306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathophysiology and treatment of negative symptoms.
    Villeneuve A
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S53-8. PubMed ID: 7533052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.
    Putzhammer A; Perfahl M; Pfeiff L; Hajak G
    Pharmacopsychiatry; 2005 May; 38(3):132-8. PubMed ID: 15902585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment.
    Peralta V; Cuesta MJ; Martinez-Larrea A; Serrano JF
    Am J Psychiatry; 2000 Sep; 157(9):1461-6. PubMed ID: 10964863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H; Hunt JI; Vitiello B; Simpson GM
    J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacologic approach to negative symptoms in schizophrenia].
    Jalenques I
    Encephale; 1995 Jun; 21 Spec No 3():35-40. PubMed ID: 7628340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Complete neuroleptic withdrawal in patients with schizophrenia with intense symptoms and resistant to treatment].
    Wolf MA; Bailly L; Diener JM; Martinet JP; Peretti S; Garneau Y
    Encephale; 1991; 17(4):255-61. PubMed ID: 1683626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clozapine withdrawal symptoms after change to sertindole in a schizophrenic patient.
    Berecz R; Glaub T; Kellermann M; de la Rubia A; Llerena A; Degrell I
    Pharmacopsychiatry; 2000 Jan; 33(1):42-4. PubMed ID: 10721883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind trial of carbamazepine in negative symptom schizophrenia.
    Nachshoni T; Levin Y; Levy A; Kritz A; Neumann M
    Biol Psychiatry; 1994 Jan; 35(1):22-6. PubMed ID: 7909450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia.
    Kim JH; Ann JH; Kim MJ
    Compr Psychiatry; 2010; 51(2):165-70. PubMed ID: 20152297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Negative symptoms, depression, anxiety and alexithymia in DSM III-R schizophrenic patients].
    Nkam I; Langlois-Thery S; Dollfus S; Petit M
    Encephale; 1997; 23(4):267-72. PubMed ID: 9417392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome.
    Malaspina D; Goetz RR; Yale S; Berman A; Friedman JH; Tremeau F; Printz D; Amador X; Johnson J; Brown A; Gorman JM
    Am J Psychiatry; 2000 Jun; 157(6):994-1003. PubMed ID: 10831482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating subjective domains of antipsychotic-induced adverse effects using heart rate variability.
    Chang JS; Hwang SS; Yi SH; Kim Y; Lee YS; Kim YS; Jung HY
    Psychiatry Clin Neurosci; 2015 May; 69(5):283-91. PubMed ID: 25066617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Covariation between motor signs and negative symptoms in drug-naive subjects with schizophrenia-spectrum disorders before and after antipsychotic treatment.
    Peralta V; de Jalón EG; Campos MS; Cuesta MJ
    Schizophr Res; 2018 Oct; 200():85-91. PubMed ID: 28864283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A discriminant validity study of negative symptoms with a special focus on depression and antipsychotic medication.
    Lewine RR
    Am J Psychiatry; 1990 Nov; 147(11):1463-6. PubMed ID: 1977328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attitudes Toward Medications and the Relationship to Outcomes in Patients with Schizophrenia.
    Campbell AH; Scalo JF; Crismon ML; Barner JC; Argo TR; Lawson KA; Miller A
    Clin Schizophr Relat Psychoses; 2018; 12(1):12-22. PubMed ID: 26218237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.